1 September 18, 2012 Dr. Keiji Kijima, Secretary General, IPEC Japan Topics for Pharmaceutical Excipients Update in IPEC Japan Agenda JPE (Japanese Pharmaceutical Excipients) JP (Japanese Pharmacopoeia),JP16,JP16-I MF (Master File System) GMP Software (Partial Amendment of the List of JP Articles for Exception to the Application of GMP Software) GAB (GMP Auditing Board) Pharmaceutical Excipients Pharmaceutical Excipients are substances(s) other than drug substance(s) contained in preparations which are used to increase the utility of the preparation, to enable manufacturing of drug products easy, to keep product’s integrity, to improve the appearance of a formulation and so forth. Pharmaceutical Excipients For these purposes, suitable excipients may be added in the drug manufacturing. The excipients used, however, must be non- toxic, harmless and pharmacologically inactive in the amount administered and must not interfere with the therapeutic efficacy or the quality test of the preparations. (JP16)
12
Embed
Topics for Pharmaceutical Excipients Update in IPEC Japan · Pharmaceutical Excipients Pharmaceutical Excipients are substances(s) other than drug substance(s) contained in preparations
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
1
September 18, 2012 Dr. Keiji Kijima, Secretary General, IPEC Japan
Topics for Pharmaceutical Excipients Update in IPEC Japan
Agenda
JPE (Japanese Pharmaceutical Excipients)
JP (Japanese Pharmacopoeia),JP16,JP16-I
MF (Master File System)
GMP Software (Partial Amendment of the List of JP
Articles for Exception to the Application of GMP Software)
GAB (GMP Auditing Board)
Pharmaceutical Excipients
Pharmaceutical Excipients are substances(s) other than drug substance(s) contained in preparations which are used to increase the utility of the preparation, to enable manufacturing of drug products easy, to keep product’s integrity, to improve the appearance of a formulation and so forth.
Pharmaceutical Excipients
For these purposes, suitable excipients may be added in the drug manufacturing. The excipients used, however, must be non-toxic, harmless and pharmacologically inactive in the amount administered and must not interfere with the therapeutic efficacy or the quality test of the preparations. (JP16)
2
JPE
Public consultation
Study Committee
IPEC Japan (Council)
Notification
Proposal
Japanese Pharmaceutical Excipient (JPE)
As preparation technologies are advanced and preparation designs are diversified, the role of pharmaceutical excipients is increasing in the characteristics such as dissolution, stability, solubility, etc.
Japanese Pharmaceutical Excipient (JPE)
Ministry of Health, Labor and Welfare (MHLW) announced the standards of the pharmaceutical excipients not included in Japanese Pharmacopoeia by the publication of ‘Japanese Pharmaceutical Excipients’ .
Japanese Pharmaceutical Excipients 1993→ 206 monographs
Japanese Pharmaceutical Excipients/Supplement 1994→
92 monographs supplied and
1 monograph deleted
---Total 297 monographs
Japanese Pharmaceutical Excipient (JPE)
3
TOTAL MONOGRPHS
JPE 1996 → 99 monographs supplied
→ Total monographs 396
Japanese Pharmaceutical Excipients 1998
→ 42 monographs supplied and
2 monographs deleted
---Total 436 monographs
TOTAL MONOGRPHS
Japanese Pharmaceutical Excipients 2003 → 44 monographs added
and 1 monographs deleted
---Total 479
FOR THE REVISED JAPANESE PHARMACEUTICAL EXCIPIENTS (JPE) 2012
MHLW started the committee for the
revision of JPE in 2010.
The committee has been held 9 times till
Dec. 2011.
[Expected: Revised---approx. 43 monographs;
New---approx. 12 monographs]
FOR THE REVISED JAPANESE PHARMACEUTICAL EXCIPIENTS (JPE) 2012
The public comment was collected in March of 2012.
→ A notification will be given by a
chief of the bureau in charge for the
enforcement during this fiscal year.
4
FOR THE REVISED JAPANESE PHARMACEUTICAL EXCIPIENTS (JPE) 2012
(ACCORDING TO THE ANNOUNCEMENT IN THE PUBLIC COMMENT)
JPE consists of pharmaceutical excipients not included in Japanese Pharmacopoeia as well as those having precedent use and often used for the marketable pharmaceutical preparations.
There are also pharmaceutical excipients specified in
attachment in the application of approval of medicines
→ Therefore, it is useful for pharmaceutical
companies to apply for the approval of medicines.
Situation of Japanese Pharmaceutical Excipients (JPE)
Situation of Japanese Pharmaceutical Excipients (JPE)
The pharmaceutical excipients,
not applied to GMP, are applicable to SELF-IMPOSED STANDARDS FOR MANUFACTURING CONTROL OF PHARMACEUTICAL EXCIPIENTS (SELF-IMPOSED GMP).
Judgment of advisability
JPE is provided to determine the standards concerning General Notices, Preparations, Descriptions, Storages, etc. The pharmaceutical excipients are to be tested according to the provisions given in General Notice, General Tests and the pertinent monographs.
5
Judgment of advisability
The items of the Description in the monographs are given for the information, and should not be taken as indicating standards for conformity.
Situation of Japanese Pharmaceutical Excipients (JPE)
Unless otherwise specified in General Notices, General Tests and the pertinent monographs, the provisions given in General Notice, General Tests in JP 16 shall be applied.
Situation of Japanese Pharmaceutical Excipients (JPE)
For pharmaceutical excipients specified in JPE Monographs which are manufactured as source materials derived from animals, the relevant animals must be healthy in principle, unless otherwise specified.
Pursuant to Paragraph 1, Article 41 of the Pharmaceutical Affairs Law (Law No.145, 1960), the Japanese Pharmacopoeia (hereinafter referred to as “new Pharmacopoeia”), which has been established as follows*, shall be applied on April 1, 2011. *The term “as follows” here indicates the contents of the Japanese Pharmacopoeia Sixteenth Edition from General Notices to Ultraviolet-visible Reference Spectra (pp.1-2131)
JP16 The Ministry of Health, Labour and walfare
Ministerial Notification No.65
6
The official name of this pharmacopoeia is 第十六改正日本薬局方, and may be abbreviated as 日局十六,日局16, JP XVI or JP 16.
The English name of the pharmacopoeia is The Japanese Pharmacopoeia, Sixteenth Edition.
Based on the Revised Pharmaceutical Affairs Law which was enforced on April 1, 2005, Master File Systems (MF) had been implemented ever since in Japan.
However, concerning existing pharmaceutical excipients, it is considered appropriate to refrain from submitting application of MF in Japan at present based on the PFSB/ELD Notification No.0210004 issued by Ministry of Health, Labor and Welfare on February 10, 2005.
Master File System for Drug Substances
8
Scope of MF Utilization
Applications of MF registrations and changes to registered contents and notifications of minor changes to the registered contents shall be submitted to the Pharmaceuticals and Medical Devices Agency (hereinafter referred to as “PMDA”), pursuant to the procedures and forms specified in the Enforcement Regulations of the Pharmaceutical Affairs Law (MHW Ministerial Ordinance No.1, 1961).
Items for registration
The following raw materials to be used for the manufacture of pharmaceuticals and medical devices can be registered in MF.
Items for registration
1. Drug substances, intermediates and pharmaceutical product materials (materials of pharmaceutical products with special dosage form, etc.)
2. New excipients and pre-mix excipients with a different composition ratio from existing ones
3. Materials for medical devices
4. Containers / packaging materials
Items for registration
Drug substances, intermediates and pharmaceutical product materials (materials of pharmaceutical products with special dosage form, etc.) used for OTC drugs (excluding OTC with new active ingredients or those with their active ingredients still in the reexamination period) are not appropriate for registration in MF, as it is considered that their quality and safety are already established even with existing specification and test methods.
9
Exception to the Application of GMP Software
As the pharmaceutical excipients in JP 16 are generally classified as ‘Medicine’, they should follow the GMP standard. Among them, 108 monographs receive the application of the GMP HARDWARE, but avoid the application of GMP SOFTWARE.
Partial Amendment of the List of JP Articles for the Exception to the Application of GMP Software (January 17, 2012)
There is a list of JP articles (which are exclusively used for the production of drugs) to which the manufacturing control and quality control rule (GMP Software) specified in the MHLW Notice No. 42 of 2004 does not apply. This list has been amended this time. There are some changes in the title names and new inclusion of Trehalose Hydrate, and total number becomes 108 articles.
☆ According to MHLW Ministerial Ordinance about GQP;
“The manufacturers of APIs shall ensure that the production duties at the factory concerned are conducted properly and efficiently with manufacturing control and quality control.”
GAB (GMP Auditing Board for
Pharmaceutical Excipients)
☆ However, As for pharmaceutical excipients, the production duties are not established as legal requirements.
GAB (GMP Auditing Board for
Pharmaceutical Excipients)
☆Pharmaceutical excipients are often used in common at plural pharmaceutical companies. In that case, It is a good policy for the pharmaceutical companies to reduce an audit burden by using audit result of the 3rd party.
GAB (GMP Auditing Board for
Pharmaceutical Excipients)
11
☆The manufactures of pharmaceutical excipients can reduce a burden to accept an audit from every company that is using the same product, too.
GAB (GMP Auditing Board for
Pharmaceutical Excipients)
☆GMP Auditing Board for Pharmaceutical Excipients is established in 2005 to secure the quality of pharmaceutical excipients of our country and to raise the reliability of the manufacturers of pharmaceutical excipients.
GAB (GMP Auditing Board for
Pharmaceutical Excipients)
☆The Board evaluates the GMP situation enforced by the manufactures based on SELF-IMPOSED GMP STANDARDS, edited by IPEC Japan, and then performs appropriate authorization.
GAB (GMP Auditing Board for
Pharmaceutical Excipients)
Outline of GMP Auditing Board for Pharmaceutical Excipients
12
Advantage of GMP Auditing Board for Pharmaceutical Excipients
The board audits the pharmaceutical excipients company whether the company conducts production duties at the manufacturing site concerned properly and efficiently with manufacturing control and quality control.
→Therefore, the pharmaceutical company might secure the good quality and reliability
of the pharmaceutical excipient product effectively if passed the audition.
Comparison of ICH GMP Guide for Active Pharmaceutical Ingredients (ICH Q7a), The Joint IPEC-PQG GMP Guide (Joint GMP) and Self-imposed of GMP for Pharmaceutical Excipients (IPEC Japan GMP Guide). Comparative study of GMP guide is now under making among those of the Joint IPEC-PQG (excipient), ICH Q7A (API) and IPEC Japan (excipient). It is the purpose of this study secondarily to investigate the difference between the certification systems of Excipact etc. and our system of GAB (GMP Auditing Board for Pharmaceutical Excipents), where dependent GMP guide is different respectively, to make clear whether there is actual difference, and to make adjustment if necessary.
GAB (GMP Auditing Board for
Pharmaceutical Excipients)
IPEC Japan GMP Standard for Pharmaceutical Excipients Intended to provide guidance on self-imposed controls required for assuring the quality of pharmaceutical excipients, and to make a contribution to the development of pharmaceutical drug products of a higher quality. The content of the quality control system is reflected by the intention of the regulatory authority as a whole. Joint IPEC-PQG GMP for Pharmaceutical Excipients Covers the quality management system and the extent of GMP necessary throughout manufacturing of pharmaceutical excipients. The quality management system standard is constructed on the basis of ISO 9001. ICH Q7A GMP Guide for API Intended to help ensure that APIs meet the quality and purity characteristics that they purport to possess by manufacturing under an appropriate system for managing quality.